Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1683 of 6351
-
Engineered immune cells take aim at rare Organ-Damaging disease
Disease control Recruiting nowSystemic light chain amyloidosis (AL amyloidosis) is the most common type of systemic amyloidosis, with diverse clinical manifestations and difficulties in diagnosis and treatment. AL amyloidosis may involve multiple organs; the kidney and heart are the most commonly involved org…
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New Twice-Yearly shot aims to close cholesterol care gaps in heart disease
Disease control OngoingVictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthca…
Phase 4 • Sponsor: Duke University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common diabetes drug protect breast cancer survivors from insulin resistance?
Disease control Recruiting nowThis phase III trial evaluates how often women develop insulin resistance and type-2 diabetes and compares metformin with usual care to usual care alone in treating insulin resistance in women with stage I-III breast cancer after chemotherapy. Insulin resistance occurs when cells…
Phase 3 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Are ventilated patients starving in silence? a new study investigates
Knowledge-focused CompletedThe primary objective is to quantify the caloric and protein intake in adult participants with acute respiratory failure who start a noninvasive ventilation treatment. The main question is: \- Are participants meeting their caloric and protein target during noninvasive ventilati…
Sponsor: Università degli Studi del Piemonte Orientale Amedeo Avogadro • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
New Alzheimer's pill shows promise in Mid-Stage trial
Symptom relief Stopped earlyResearchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChE…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Real-World data suggests asciminib may help some leukemia patients
Disease control CompletedThe aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refra…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New pill takes on tough lymphoma: early trial seeks tumor shrinkage
Disease control OngoingThe primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Phase 1 • Sponsor: Treeline Biosciences, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New eye injection could shrink metastatic tumors in the eye
Disease control Recruiting nowThe primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Phase 2 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a tiny heart sensor make LVADs safer?
Disease control OngoingThe Microtech-LVAD study is designed as a prospective, single arm, multi-center early feasibility study. Approximately 15 patients will be enrolled in the study. The study will be limited to patients in whom it is decided, based on routine clinical practice, that the LVAD will be…
Sponsor: Microtech Medical Technologies, Ltd • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New calcium pill could ease burden for hypoparathyroidism patients
Disease control OngoingThis clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia in adults with hypoparathyroidism.
Phase 2 • Sponsor: Amorphical Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can tailored nutrition and exercise after ICU boost recovery?
Disease control Recruiting nowThe NUTRIREA-4 trial will test the hypothesis that an individually tailored rehabilitation program combining nutritional therapy, physiotherapy, and physical activity and started early in the ICU then continued uninterruptedly throughout the post-ICU stay and at home after hospit…
Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New pill targets common cancer mutation in early trial
Disease control Stopped earlyThis is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metasta…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New device aims to stop leaks without surgery
Symptom relief Recruiting nowThis study is a multicenter, prospective, randomized, double-blind, sham-controlled clinical trial conducted in female patients with stress urinary incontinence.
Sponsor: Ceragem Clinical Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Prostate cancer study aims to restore testosterone after Long-Term therapy
Disease control OngoingThis research study is being done to determine the rate of testosterone recovery after completing two years of treatment with the combination of relugolix and darolutamide as well as to assess the safety of the drugs when administered in combination. The names of the drugs in th…
Phase 2 • Sponsor: Atish Choudhury, MD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a single pill speed up severe flu recovery?
Symptom relief Recruiting nowThe purpose of this clinical trial is to find out if the medication called baloxavir marboxil (sold under the brand name Xofluza®) can help to reduce the time needed to recover from flu when patients need an hospitalization. Patients infected by influenza and requiring a hospital…
Phase 3 • Sponsor: Dre Pauline Vetter • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New heart valve procedure shows promise for Low-Risk patients
Disease control CompletedThe primary objective is to assess all-cause mortality, the occurrence of stroke, or rehospitalization for cardiovascular causes in low-risk "all-comers" patients following percutaneous aortic valve replacement
Sponsor: Centro Cardiologico Monzino • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy aims to boost tumor control in pancreatic cancer
Disease control Recruiting nowThis is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New balloon could save dialysis patients from repeat surgeries
Disease control OngoingA prospective, multi-center study to evaluate efficacy and safety of BSJ020R in treatment of AVF for hemodialysis
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolera…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New imaging agent could spot recurrent brain metastases more accurately
Diagnosis OngoingThis is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Perio…
Phase 2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC